Publications
- Newest First
- Most Cited
- Most Discussed
Showing 1 - 100 results of 2,804 publications
2024
- Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinomaEl Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, Sahgal P, Fortunato B, Canniff J, Nassar A, Abou Alaiwi S, Bakouny Z, Lakshminarayanan G, Savignano H, Lyons K, Matar S, Ali A, Saad E, Saliby R, Cordeiro P, Zhang Z, El Ahmar N, Laimon Y, Labaki C, Shah V, Freeman D, O'Toole J, Lee G, Hwang J, Pomerantz M, Signoretti S, Van Allen E, Xie W, Berchuck J, Viswanathan S, Braun D, Choueiri T, Freedman M, Baca S. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Reports 2024, 43: 114350. PMID: 38870013, DOI: 10.1016/j.celrep.2024.114350.
- TikTok misinformation and user engagement in female pelvic floor conditionsStephan A, Hauc S, Marks V, Bercik R, Rickey L. TikTok misinformation and user engagement in female pelvic floor conditions. Neurourology And Urodynamics 2024 PMID: 38828831, DOI: 10.1002/nau.25519.
- Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data LinkageLeapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.
- Comparative review of vasectomy guidelines and novel vasal occlusion techniquesPelzman D, Honig S, Sandlow J. Comparative review of vasectomy guidelines and novel vasal occlusion techniques. Andrology 2024 PMID: 38774918, DOI: 10.1111/andr.13665.
- Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or olderGhali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Grivas P, Hawley J, Hsieh A, Montgomery R, Wright J. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. Frontiers In Oncology 2024, 14: 1341655. PMID: 38812783, PMCID: PMC11133586, DOI: 10.3389/fonc.2024.1341655.
- Lower Urinary Tract Symptoms in US Women: Contemporary Prevalence Estimates from the RISE FOR HEALTH Study.Sutcliffe S, Falke C, Fok C, Griffith J, Harlow B, Kenton K, Lewis C, Low L, Lowder J, Lukacz E, Markland A, McGwin G, Meister M, Mueller E, Newman D, Pakpahan R, Rickey L, Rockwood T, Simon M, Smith A, Rudser K, Smith A, Brubaker L, Mueller E, Acevedo-Alvarez M, Fitzgerald C, Hardacker C, Hebert-Beirne J, Griffith J, Kenton K, Simon M, Brown O, Geynisman-Tan J, Mueller M, Markland A, Vaughan C, Coyne-Beasley T, Burgio K, Lewis C, McGwin G, Williams B, Lukacz E, LaCoursiere D, Gahagan S, Nodora J, Low L, Miller J, Smith A, McGwin G, Rudser K, Brady S, Fok C, Harlow B, Scal P, Rockwood T, Newman D, Smith A, Berry A, Bilger A, Lipman T, Klusaritz H, Stapleton A, Wyman J, Sutcliffe S, James A, Lowder J, Meister M, Rickey L, Camenga D, Cunningham S, Brubaker L, Norton J. Lower Urinary Tract Symptoms in US Women: Contemporary Prevalence Estimates from the RISE FOR HEALTH Study. Journal Of Urology 2024, 212: 124-135. PMID: 38703067, PMCID: PMC11166514, DOI: 10.1097/ju.0000000000004009.
- The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomyLokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.
- Amateur Versus Professional Users of the YO® Home Sperm Test: An Assessment of UsabilityBar-Chama N, Rabinovitch L, Honig S. Amateur Versus Professional Users of the YO® Home Sperm Test: An Assessment of Usability. Urology 2024 PMID: 38705243, DOI: 10.1016/j.urology.2024.04.001.
- PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELINGKunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDYLeapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- PD40-09 “WHAT DO YOU MEAN BY a ‘RISK’? I’D LIKE TO SEE THAT PRESENTED BETTER”: A QUALITATIVE STUDY EXPLORING PATIENT PREFERENCES ABOUT PROSTATE CANCER RISK ASSESSMENT AND COMMUNICATIONSutherland R, Golos A, Leapman M. PD40-09 “WHAT DO YOU MEAN BY a ‘RISK’? I’D LIKE TO SEE THAT PRESENTED BETTER”: A QUALITATIVE STUDY EXPLORING PATIENT PREFERENCES ABOUT PROSTATE CANCER RISK ASSESSMENT AND COMMUNICATION. Journal Of Urology 2024, 211: e823. DOI: 10.1097/01.ju.0001009356.04608.d5.09.
- HF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVELokeshwar S, Shaheen D, Choksi A, Patel M, Rahman S, Martin T, Hesse D, Leapman M. HF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVE. Journal Of Urology 2024, 211: e282. DOI: 10.1097/01.ju.0001008828.35887.de.10.
- MP24-10 TRENDS IN UROLOGY PRACTICE CONSOLIDATION AND PRIVATE EQUITY INVESTMENT FROM 2011-2023Golos A, Nie J, Hsiang W, Davies B, Filson C, Leapman M. MP24-10 TRENDS IN UROLOGY PRACTICE CONSOLIDATION AND PRIVATE EQUITY INVESTMENT FROM 2011-2023. Journal Of Urology 2024, 211: e396. DOI: 10.1097/01.ju.0001008860.46052.c4.10.
- MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEMKunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSYWebb L, Diaz G, Velasquez E, Goberdhan S, Khajir G, Sundaresan V, Leapman M, Sprenkle P. MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY. Journal Of Urology 2024, 211: e315. DOI: 10.1097/01.ju.0001008716.22569.77.12.
- PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATESLeapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- MP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMYLokeshwar S, Choksi A, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Brito J, Renzulli J, Leapman M. MP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY. Journal Of Urology 2024, 211: e947. DOI: 10.1097/01.ju.0001008852.83523.41.01.
- MP23-14 PREVALENCE OF LOWER URINARY TRACT SYMPTOMS IN THE US POPULATION: CONTEMPORARY ESTIMATES FROM THE RISE FOR HEALTH (RISE) STUDYSutcliffe S, Falke C, Fok C, Harlow B, Kenton K, Lewis C, Low L, Lowder J, Lukacz E, Markland A, McGwin G, Meister M, Mueller E, Newman D, Pakpahan R, Rickey L, Rockwood T, Smith A, Smith E, Rudser K, Smith A, Consortium F. MP23-14 PREVALENCE OF LOWER URINARY TRACT SYMPTOMS IN THE US POPULATION: CONTEMPORARY ESTIMATES FROM THE RISE FOR HEALTH (RISE) STUDY. Journal Of Urology 2024, 211: e387. DOI: 10.1097/01.ju.0001008776.99097.8a.14.
- Results of a Study Examining the Use of OnabotulinumtoxinA in Pediatric Patients With Overactive BladderHoebeke P, Hittelman A, Jenkins B, Geib T, Titanji W, Bogaert G. Results of a Study Examining the Use of OnabotulinumtoxinA in Pediatric Patients With Overactive Bladder. Journal Of Pediatric Urology 2024 DOI: 10.1016/j.jpurol.2024.04.019.
- MP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORTShumaker L, Fang A, Kaneko M, Ramacciotti L, Prakash N, Das A, Patel H, Khajir G, Fan R, Wang S, Pineault K, Sidana A, Gupta G, Filson C, Wysock J, Siddiqui M, Sonn G, Sprenkle P, Ross A, Jarrard D, Punnen S, Abreu A, Rais-Bahrami S. MP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORT. Journal Of Urology 2024, 211: e316. DOI: 10.1097/01.ju.0001008716.22569.77.16.
- MP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRIDiaz G, Webb L, Khajir G, Sprenkle P. MP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRI. Journal Of Urology 2024, 211: e313. DOI: 10.1097/01.ju.0001008716.22569.77.09.
- MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?Webb L, Diaz G, Rahman S, Khajir G, Sprenkle P. MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE? Journal Of Urology 2024, 211: e504. DOI: 10.1097/01.ju.0001008936.35187.0b.04.
- MP11-15 SPERMATOCELECTOMY WITH VERSUS WITHOUT EPIDIDYMECTOMY: A SINGLE INSTITUTION EXPERIENCECahill E, Choksi A, Reddy S, Heckscher D, Rotker K, Honig S. MP11-15 SPERMATOCELECTOMY WITH VERSUS WITHOUT EPIDIDYMECTOMY: A SINGLE INSTITUTION EXPERIENCE. Journal Of Urology 2024, 211: e156. DOI: 10.1097/01.ju.0001008564.85995.11.15.
- MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NAÏVE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDYShore N, Lang J, Geynisman D, Stewart T, Gao X, Appleman L, Dreicer R, Dorff T, Berghorn E, Duperret E, Lu H, Chan E, Garmezy B, Petrylak D. MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NAÏVE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY. Journal Of Urology 2024, 211: e227. DOI: 10.1097/01.ju.0001009428.69695.82.19.
- PD34-09 PATTERNS OF CHEMOTHERAPY USE WITH PRIMARY RADIOTHERAPY FOR LOCALIZED BLADDER CANCERGhali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Montgomery R, Wright J. PD34-09 PATTERNS OF CHEMOTHERAPY USE WITH PRIMARY RADIOTHERAPY FOR LOCALIZED BLADDER CANCER. Journal Of Urology 2024, 211: e722. DOI: 10.1097/01.ju.0001008768.36634.79.09.
- MP15-18 MOLECULAR CHARACTERIZATION OF URETHRAL CANCER AND COMPARISON WITH BLADDER CANCERGhali F, Galipeau P, Yang M, Dill-McFarland K, Ha G, Montgomery R, Wright J, Lam H. MP15-18 MOLECULAR CHARACTERIZATION OF URETHRAL CANCER AND COMPARISON WITH BLADDER CANCER. Journal Of Urology 2024, 211: e237. DOI: 10.1097/01.ju.0001009500.87761.bf.18.
- Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder CancerKoehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.
- Symmetric Consistency with Cross-Domain Mixup for Cross-Modality Cardiac SegmentationCai Z, Xin J, Dong S, Onofrey J, Zheng N, Duncan J. Symmetric Consistency with Cross-Domain Mixup for Cross-Modality Cardiac Segmentation. 2024, 1536-1540. DOI: 10.1109/icassp48485.2024.10447304.
- Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Einstein D, Catalano P, Hammers H, Regan M. Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal For ImmunoTherapy Of Cancer 2024, 12: e008293. PMID: 38604810, PMCID: PMC11015345, DOI: 10.1136/jitc-2023-008293.
- Magnetic Resonance Imaging in Prostate Cancer ScreeningFazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10 PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.
- Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomesSaliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, Saad E, Kane M, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer R, Powles T, Rini B, Albiges L, Pal S, McGregor B, McKay R, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 2024, 42: 732-735. PMID: 38579722, PMCID: PMC11130783, DOI: 10.1016/j.ccell.2024.03.002.
- ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancerSutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.
- Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell CarcinomaRahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.
- Editorial: Ex vivo onco-testis microdissectionHonig S. Editorial: Ex vivo onco-testis microdissection. Fertility And Sterility 2024, 121: 970. PMID: 38554764, DOI: 10.1016/j.fertnstert.2024.03.023.
- Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learningGross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 1-13. PMID: 38536464, DOI: 10.1007/s00330-024-10624-8.
- Abstract 5673: Transposable element expression patterns in epigenetic mutational subtypes of clear cell renal cell carcinomaMeli K, Ricker C, Camp S, Smith C, Labaki C, Saad E, Soulati H, Reardon B, Park J, Vokes N, Vincent B, Choueiri T, Braun D, Van Allen E. Abstract 5673: Transposable element expression patterns in epigenetic mutational subtypes of clear cell renal cell carcinoma. Cancer Research 2024, 84: 5673-5673. DOI: 10.1158/1538-7445.am2024-5673.
- Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell CarcinomaHan S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.
- RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRISundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.
- A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative studyLokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Brito J, Renzulli J, Sprenkle P, Michael M. A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study. European Urology 2024, 85: s1101. DOI: 10.1016/s0302-2838(24)00884-4.
- Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy HistopathologyZeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Reply by AuthorsSterling J, Simhan J, Flynn B, Rusilko P, França W, Ramirez E, Angulo J, Martins F, Patel H, Higgins M, Swerdloff D, Nikolavsky D. Reply by Authors. Journal Of Urology 2024, 211: 607-607. PMID: 38382012, DOI: 10.1097/ju.0000000000003888.
- (121) Utilizing ChatGPT for Urology Trainee Simulation of Peyronie’s Disease CounselingReddy S, Smani S, Honig S, Harnisch B, Rotker K. (121) Utilizing ChatGPT for Urology Trainee Simulation of Peyronie’s Disease Counseling. The Journal Of Sexual Medicine 2024, 21: qdae001.115. DOI: 10.1093/jsxmed/qdae001.115.
- (013) How do Sexual Medicine Specialists Handle Patient Counseling and Penile Rehabilitation in Patients Undergoing Robotic Assisted Radical Prostatectomy (ralp): Trends in Pre Op and Post Operative ManagementHeckscher D, Honig S, Rotker K. (013) How do Sexual Medicine Specialists Handle Patient Counseling and Penile Rehabilitation in Patients Undergoing Robotic Assisted Radical Prostatectomy (ralp): Trends in Pre Op and Post Operative Management. The Journal Of Sexual Medicine 2024, 21: qdae001.011. DOI: 10.1093/jsxmed/qdae001.011.
- (376) High Capability of ChatGPT to Answer Common Patient Questions on Vasectomy Reviewed by Sexual Medicine SpecialistsReddy S, Harnisch B, Honig S, Rotker K. (376) High Capability of ChatGPT to Answer Common Patient Questions on Vasectomy Reviewed by Sexual Medicine Specialists. The Journal Of Sexual Medicine 2024, 21: qdae001.361. DOI: 10.1093/jsxmed/qdae001.361.
- Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Association Between Pelvic Lymph Node Dissection and Survival Among Patients with Prostate Cancer Treated with Radical ProstatectomyKim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association Between Pelvic Lymph Node Dissection and Survival Among Patients with Prostate Cancer Treated with Radical Prostatectomy. Prostate International 2024 DOI: 10.1016/j.prnil.2024.01.002.
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).Aragon-Ching J, Petrylak D, Sridhar S, Gupta S, Grivas P, Powles T, Gurney H, Jacob N, Tyroller K, Guenther S, Bellmunt J. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI). Journal Of Clinical Oncology 2024, 42: 600-600. DOI: 10.1200/jco.2024.42.4_suppl.600.
- SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.Cheng H, Callis S, Lin D, Yu E, Dorff T, Kase A, Tangen C, Petrylak D, Lerner S. SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations. Journal Of Clinical Oncology 2024, 42: tps354-tps354. DOI: 10.1200/jco.2024.42.4_suppl.tps354.
- Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.Saliby R, Xie W, Wells J, Saad E, Eid M, Labaki C, Semaan K, Ferrier E, Lemelin A, Suárez C, Ruiz-Morales J, Powles T, Wood L, Ebrahimi H, de Velasco G, Takemura K, Agarwal N, Braun D, Heng D, Choueiri T. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study. Journal Of Clinical Oncology 2024, 42: 400-400. DOI: 10.1200/jco.2024.42.4_suppl.400.
- Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.El Ahmar N, Matar S, Jegede O, Nabil Laimon Y, Savla V, Bagheri Sheshdeh A, Denize T, Mohanna R, Choueiri T, Catalano P, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial. Journal Of Clinical Oncology 2024, 42: 448-448. DOI: 10.1200/jco.2024.42.4_suppl.448.
- Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation.Semaan K, El Zarif T, Seo J, Eid M, Canniff J, Fortunato B, Savignano H, Davidsohn M, Lakshminarayanan G, Saad E, Saliby R, Bakouny Z, Matar S, Nuzzo P, Berchuck J, Signoretti S, Braun D, Freedman M, Baca S, Choueiri T. Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation. Journal Of Clinical Oncology 2024, 42: 449-449. DOI: 10.1200/jco.2024.42.4_suppl.449.
- Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.Saad E, Labaki C, Miron B, Park J, Bakouny Z, Nassar A, Saliby R, Semaan K, Eid M, Meli K, Nabil Laimon Y, Geynisman D, Kokate R, Braun D, Signoretti S, McGregor B, Plimack E, Choueiri T, Van Allen E, Zibelman M. Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2024, 42: 459-459. DOI: 10.1200/jco.2024.42.4_suppl.459.
- Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).Labaki C, Alchoueiry M, Bi K, Zhang L, Hobeika C, Bakouny Z, El Ahmar N, Matar S, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Saad E, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). Journal Of Clinical Oncology 2024, 42: 476-476. DOI: 10.1200/jco.2024.42.4_suppl.476.
- Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).Serzan M, Jegede O, Bilen M, Braun D, Einstein D, Haas N, Hammers H, King J, Runcie K, Sosman J, Sternberg C, Yang Y, Choueiri T, Signoretti S, Atkins M. Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). Journal Of Clinical Oncology 2024, 42: tps492-tps492. DOI: 10.1200/jco.2024.42.4_suppl.tps492.
- Multi-Institutional Outcomes of Dorsal Onlay Buccal Mucosal Graft Urethroplasty in Patients With Postprostatectomy, Postradiation Anastomotic StenosisSterling J, Simhan J, Flynn B, Rusilko P, França W, Ramirez E, Angulo J, Martins F, Patel H, Higgins M, Swerdloff D, Nikolavsky D. Multi-Institutional Outcomes of Dorsal Onlay Buccal Mucosal Graft Urethroplasty in Patients With Postprostatectomy, Postradiation Anastomotic Stenosis. Journal Of Urology 2024, 211: 596-604. PMID: 38275201, DOI: 10.1097/ju.0000000000003848.
- Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Grivas P, Pouessel D, Park C, Barthelemy P, Bupathi M, Petrylak D, Agarwal N, Gupta S, Fléchon A, Ramamurthy C, Davis N, Recio-Boiles A, Sternberg C, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa S, Loriot Y. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. Journal Of Clinical Oncology 2024, 42: 1415-1425. PMID: 38261969, PMCID: PMC11095901, DOI: 10.1200/jco.22.02835.
- TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomesLoriot Y, Petrylak D, Kalebasty A, Fléchon A, Jain R, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar A, Kyriakopoulos C, Pouessel D, Sternberg C, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa S. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals Of Oncology 2024, 35: 392-401. PMID: 38244927, DOI: 10.1016/j.annonc.2024.01.002.
- Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse modelWang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, Sun J, Braun D, Choueiri T, Wu C, Jones K, Nguyen Q, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman G, Hemberg M, Marasco W. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. IScience 2024, 27: 108879. PMID: 38327771, PMCID: PMC10847687, DOI: 10.1016/j.isci.2024.108879.
- Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomicsGross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 1-10. PMID: 38217704, DOI: 10.1007/s00330-023-10495-5.
- Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMilowsky M, O'Donnell P, Hoimes C, Petrylak D, Flaig T, Moon H, Friedlander T, Mar N, McKay R, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret A, Yu Y, Dillon R, Kataria R, Beaumont J, Purnajo I, Rosenberg J. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Journal Of Clinical Oncology 2024, 42: 1403-1414. PMID: 38215355, PMCID: PMC11095879, DOI: 10.1200/jco.23.01547.
- Patient-Specific Heart Geometry Modeling for Solid Biomechanics Using Deep LearningPak D, Liu M, Kim T, Liang L, Caballero A, Onofrey J, Ahn S, Xu Y, McKay R, Sun W, Gleason R, Duncan J. Patient-Specific Heart Geometry Modeling for Solid Biomechanics Using Deep Learning. IEEE Transactions On Medical Imaging 2024, 43: 203-215. PMID: 37432807, PMCID: PMC10764002, DOI: 10.1109/tmi.2023.3294128.
- Association Between Maternal Depression and Lower Urinary Tract Symptoms in Their Primary School-Age DaughtersCunningham S, Lindberg S, Joinson C, Shoham D, Chu H, Newman D, Epperson N, Brubaker L, Low L, Camenga D, LaCoursiere D, Meister M, Kenton K, Sutcliffe S, Markland A, Gahagan S, Coyne-Beasley T, Berry A, Brubaker L, Mueller E, Acevedo-Alvarez M, Fitzgerald C, Hardacker C, Hebert-Beirne J, Lavender M, Shoham D, Kenton K, Griffith J, Simon M, Geynisman-Tan J, Markland A, Coyne-Beasley T, Burgio K, Lewis C, McGwin G, Vaughan C, Williams B, Lukacz E, Gahagan S, LaCoursiere D, Nodora J, Miller J, Low L, Harlow B, Rudser K, Brady S, Chu H, Fok C, Scal P, Rockwood T, Lindberg S, Newman D, Smith A, Berry A, Bilger A, Klusaritz H, Lipman T, Stapleton A, Wyman J, Sutcliffe S, James A, Lowder J, Meister M, Rickey L, Camenga D, Cunningham S, Brubaker L, Barthold J. Association Between Maternal Depression and Lower Urinary Tract Symptoms in Their Primary School-Age Daughters. Journal Of Wound Ostomy And Continence Nursing 2024, 51: 53-60. PMID: 38215298, PMCID: PMC10794027, DOI: 10.1097/won.0000000000001039.
2023
- Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell CarcinomaChoueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, Larkin J, Mu X, Pu J, Teresi R, di Pietro A, Robbins P, Motzer R. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery 2023, 14: of1-of18. PMID: 38385846, PMCID: PMC10905671, DOI: 10.1158/2159-8290.cd-23-0680.
- Unsupervised Domain Adaptation by Cross-Prototype Contrastive Learning for Medical Image SegmentationCai Z, Xin J, Dong S, You C, Shi P, Zeng T, Zhang J, Onofrey J, Zheng N, Duncan J. Unsupervised Domain Adaptation by Cross-Prototype Contrastive Learning for Medical Image Segmentation. 2023, 00: 819-824. DOI: 10.1109/bibm58861.2023.10386055.
- A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDjureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.
- Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional StudyMarks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.
- Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.
- Clinical Trials and Climate Change: Doing Our Part While Pursuing ProgressRahman S, Ryan S, Kim J, Kenney P, Ghali F. Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress. European Urology Focus 2023, 9: 861-862. PMID: 38042649, DOI: 10.1016/j.euf.2023.11.011.
- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial CarcinomaPetrylak D, Eigl B, George S, Heath E, Hotte S, Chism D, Nabell L, Picus J, Cheng S, Appleman L, Sonpavde G, Morgans A, Pourhosseini P, Wu R, Standley L, Croitoru R, Yu E. Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research 2023, 30: of1-of11. PMID: 37861407, PMCID: PMC10767306, DOI: 10.1158/1078-0432.ccr-22-3627.
- LiverHccSeg: A publicly available multiphasic MRI dataset with liver and HCC tumor segmentations and inter-rater agreement analysisGross M, Arora S, Huber S, Kücükkaya A, Onofrey J. LiverHccSeg: A publicly available multiphasic MRI dataset with liver and HCC tumor segmentations and inter-rater agreement analysis. Data In Brief 2023, 51: 109662. PMID: 37869619, PMCID: PMC10587725, DOI: 10.1016/j.dib.2023.109662.
- Trends in new and persistent opioid use in older adults with and without cancerBaum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.
- Cross-Attention for Improved Motion Correction in Brain PETCai Z, Zeng T, Lieffrig E, Zhang J, Chen F, Toyonaga T, You C, Xin J, Zheng N, Lu Y, Duncan J, Onofrey J. Cross-Attention for Improved Motion Correction in Brain PET. 2023, 14312: 34-45. PMID: 38174216, PMCID: PMC10758996, DOI: 10.1007/978-3-031-44858-4_4.
- Fast Reconstruction for Deep Learning PET Head Motion CorrectionZeng T, Zhang J, Lieffrig E, Cai Z, Chen F, You C, Naganawa M, Lu Y, Onofrey J. Fast Reconstruction for Deep Learning PET Head Motion Correction. 2023, 14229: 710-719. PMID: 38174207, PMCID: PMC10758999, DOI: 10.1007/978-3-031-43999-5_67.
- HIGH CAPABILITY OF CHATGPT TO ANSWER COMMON PATIENT QUESTIONS ENCOUNTERED BY REPRODUCTIVE UROLOGISTSReddy S, Rotker K, Honig S, Harnisch B. HIGH CAPABILITY OF CHATGPT TO ANSWER COMMON PATIENT QUESTIONS ENCOUNTERED BY REPRODUCTIVE UROLOGISTS. Fertility And Sterility 2023, 120: e254. DOI: 10.1016/j.fertnstert.2023.08.714.
- 1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)McKay R, Xie W, Leucht K, Jegede O, Braun D, Atkins M, Grimm M, Choueiri T. 1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC). Annals Of Oncology 2023, 34: s1017-s1018. DOI: 10.1016/j.annonc.2023.09.1122.
- 1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinomaSaliby R, Jammihal T, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, Zarif T, Ahmar N, Laimon Y, Heng D, Signoretti S, Van Allen E, Choueiri T, Shukla S, Braun D. 1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma. Annals Of Oncology 2023, 34: s1017. DOI: 10.1016/j.annonc.2023.09.1121.
- 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)Sridhar S, O'Donnell P, Flaig T, Rosenberg J, Hoimes C, Milowsky M, Srinivas S, George S, McKay R, Petrylak D, Barata P, Hwang C, Cruz-Correa M, Iafolla M, Mckean M, Dreicer R, Brancato S, Lukas J, Yu Y, Moon H. 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC). Annals Of Oncology 2023, 34: s1203. DOI: 10.1016/j.annonc.2023.09.1014.
- 1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutationsPetrylak D, Garmezy B, Shen J, Kalebasty A, Sartor O, Dreicer R, Agarwal N, Hussain M, Percent I, Heath E, Gedrich R, Yu T, Healey D, Parameswaran J, Sternberg C, Gao X. 1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations. Annals Of Oncology 2023, 34: s973-s974. DOI: 10.1016/j.annonc.2023.09.2751.
- Embracing Challenges and Opportunities Posed by New Technologies in Urologic CareLeapman M. Embracing Challenges and Opportunities Posed by New Technologies in Urologic Care. Urology Practice 2023, 11: 7-8. PMID: 37747948, DOI: 10.1097/upj.0000000000000459.
- Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelinesWang C, Meriggiola M, Amory J, Barratt C, Behre H, Bremner W, Ferlin A, Honig S, Kopa Z, Lo K, Nieschlag E, Page S, Sandlow J, Sitruk‐Ware R, Swerdloff R, Wu F, Goulis D. Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelines. Andrology 2023 PMID: 37727884, DOI: 10.1111/andr.13525.
- Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before MaintenanceSridhar S, Powles T, Climent Durán M, Park S, Massari F, Thiery-Vuillemin A, Valderrama B, Ullén A, Tsuchiya N, Aragon-Ching J, Gupta S, Petrylak D, Bellmunt J, Wang J, Laliberte R, di Pietro A, Costa N, Grivas P, Sternberg C, Loriot Y. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. European Urology 2023, 85: 154-163. PMID: 37714742, DOI: 10.1016/j.eururo.2023.08.001.
- EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M, Petrylak D. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆. Annals Of Oncology 2023, 34: 1047-1054. PMID: 37678672, DOI: 10.1016/j.annonc.2023.08.016.
- Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer.Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song W, Fujiwara N, Li P, Mendizabal I, Petrylak D, Kelly W, Reddy E, Wang L, Schiewer M, Lujambio A, Karnes J, Knudsen K, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discovery 2023, 13: 2584-2609. PMID: 37676710, PMCID: PMC10714140, DOI: 10.1158/2159-8290.cd-23-0306.
- Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic NeoplasmsLabaki C, Al-Choueiry M, Nyman J, Hou Y, Bi K, Zhang L, Hobeika C, Bakouny Z, Priolo C, Khabibullin D, Schindler N, Fu J, Camp S, Saliby R, Saad E, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms. The Oncologist 2023, 28: s7-s8. PMCID: PMC10445568, DOI: 10.1093/oncolo/oyad216.011.
- Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)Saad E, Labaki C, Saliby R, Bakouny Z, Song L, Wall M, Pan W, Semaan K, Eid M, Gwo-Shu M, Braun D, Liu X, Choueiri T. Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC). The Oncologist 2023, 28: s4-s5. PMCID: PMC10445570, DOI: 10.1093/oncolo/oyad216.007.
- Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinomaSaliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. The Oncologist 2023, 28: s15-s16. PMCID: PMC10445571, DOI: 10.1093/oncolo/oyad216.026.
- Preferences for Public Health Messaging Related to Bladder Health in Adolescent and Adult WomenBurgio K, Cunningham S, Newman D, Low L, Nodora J, Lipman T, Klusaritz H, James A, Rickey L, Gahagan S, Hebert-Beirne J, Kenton K, Williams B. Preferences for Public Health Messaging Related to Bladder Health in Adolescent and Adult Women. Journal Of Women's Health 2023, 32: 1120-1135. PMID: 37610853, PMCID: PMC10541935, DOI: 10.1089/jwh.2022.0463.
- Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastasesSchoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
- Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancerLeapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.
- Abstract A013: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinomaBraun D, Keskin D, Shukla S, McGregor B, Schindler N, Blass E, Klaeger S, Pomerance L, Sarkizova S, Li S, Southard J, Moranzoni G, Pedersen C, Liu Y, Chang S, Hirsch M, LeBoeuf N, Mossanen M, Chea V, Carulli I, Olive O, Mehndiratta A, Greenslade H, Oliveira G, Iorgulescu J, Signoretti S, Aster J, Elagina L, Leshchiner I, Getz G, Harden M, Gabriel S, Olsen L, Neuberg D, Fritsch E, Hacohen N, Livak K, Carr S, Ott P, Wu C, Choueiri T. Abstract A013: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma. Cancer Research 2023, 83: a013-a013. DOI: 10.1158/1538-7445.kidney23-a013.
- Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockadeHugaboom M, Ruthen N, Jegede O, Schindler N, Wirth L, Kyrysyuk S, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D, Street K. Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockade. Cancer Research 2023, 83: b013-b013. DOI: 10.1158/1538-7445.kidney23-b013.
- Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC)Semaan K, Zarif T, Eid M, Shah V, Fortunato B, Saliby R, Nassar A, Alaiwi S, Seo J, Labaki C, Bakouny Z, Matar S, Ahmar N, Laimon Y, Lee G, Pomerantz M, Berchuck J, Signoretti S, Van Allen E, Choueiri T, Braun D, Freedman M, Baca S. Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC). Cancer Research 2023, 83: a029-a029. DOI: 10.1158/1538-7445.kidney23-a029.
- Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironmentAlchoueiry M, Labaki C, Zhang L, Hou Y, Bi K, Hobeika C, Wells J, Takemura K, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Saliby R, Saad E, Salem S, Daou M, McKay R, Pal S, Heng D, Van Allen E, Shukla S, Choueiri T, Braun D, Henske E. Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironment. Cancer Research 2023, 83: b019-b019. DOI: 10.1158/1538-7445.kidney23-b019.
- Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinomaBraun D, Keskin D, Shukla S, McGregor B, Schindler N, Blass E, Klaeger S, Pomerance L, Sarkizova S, Li S, Southard J, Moranzoni G, Pedersen C, Liu Y, Chang S, Hirsch M, LeBoeuf N, Mossanen M, Chea V, Carulli I, Olive O, Mehndiratta A, Greenslade H, Oliveira G, Iorgulescu J, Signoretti S, Aster J, Elagina L, Leshchiner I, Getz G, Harden M, Gabriel S, Olsen L, Neuberg D, Fritsch E, Hacohen N, Livak K, Carr S, Ott P, Wu C, Choueiri T. Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma. Cancer Research 2023, 83: pr015-pr015. DOI: 10.1158/1538-7445.kidney23-pr015.
- Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrationsŚlusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.
- Attitudes towards disposition of cryopreserved sperm in the event of death.Buller D, Harnisch B, Lyall V, Goltzman M, Neuber E, Bartolucci A, Honig S. Attitudes towards disposition of cryopreserved sperm in the event of death. Canadian Journal Of Urology 2023, 30: 11613-11618. PMID: 37633289.
- Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapyWang Z, Muthusamy V, Petrylak D, Anderson K. Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy. Npj Precision Oncology 2023, 7: 70. PMID: 37479885, PMCID: PMC10362036, DOI: 10.1038/s41698-023-00417-5.
- Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the USKc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell CarcinomaLabaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.